Novel bergamot oil nanospanlastics combined with PUVB therapy as a clinically translatable approach for vitiligo treatment.


Journal

Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061

Informations de publication

Date de publication:
12 2019
Historique:
pubmed: 13 6 2019
medline: 2 4 2020
entrez: 13 6 2019
Statut: ppublish

Résumé

The impact of nanomedicine has grown in the current decade; however, only very few clinical translational attempts have been realized. Therefore in the present study, we hypothesized that bergamot oil, a psoralen-containing oil, would produce an optimized melanogenic effect in the clinical treatment of vitiligo when loaded within an elastic nanocarrier (spanlastics) and combined with PUVB for activation of psoralens. Spanlastics were prepared and characterized for particle size, physical stability, in vitro release, thermal behavior, deformability, morphology, and in vitro photostability. The efficacy of the selected formula was tested histopathologically on rat skin and clinically translated in patients suffering from vitiligo. Results revealed that the spanlastics were of reasonable nanosize, deformable, and provided sustained release of bergamot oil. The incorporation of bergamot oil within spanlastics improved its photostability and its photodynamic activity. Spanlastics exhibited promising clinical results in terms of extent and onset of repigmentation in vitiligo patients. Therefore, it can be concluded that spanlastics can be introduced as a promising nanotreatment modality for vitiligo.

Identifiants

pubmed: 31187447
doi: 10.1007/s13346-019-00653-y
pii: 10.1007/s13346-019-00653-y
doi:

Substances chimiques

Drug Carriers 0
Hexoses 0
Plant Oils 0
bergamot oil 39W1PKE3JI
sorbitan monopalmitate 77K6Z421KU
sorbitan monostearate NVZ4I0H58X

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1106-1116

Références

Eur J Pharm Biopharm. 2005 Apr;59(3):485-90
pubmed: 15760729
Photodermatol Photoimmunol Photomed. 2006 Feb;22(1):6-11
pubmed: 16436175
Pharm Dev Technol. 2019 Feb;24(2):157-165
pubmed: 29441809
Nanomedicine (Lond). 2015;10(13):2017-31
pubmed: 26135513
Eur J Pharm Sci. 2018 Sep 15;122:246-253
pubmed: 29981403
Indian J Dermatol Venereol Leprol. 2015 Sep-Oct;81(5):457-63
pubmed: 26261140
Photochem Photobiol. 1989 Dec;50(6):859-82
pubmed: 2696993
Int J Pharm. 2015 Apr 10;483(1-2):77-88
pubmed: 25666025
Drug Deliv. 2013 Nov;20(8):311-8
pubmed: 24079347
Contact Dermatitis. 1977 Oct;3(5):225-39
pubmed: 589995
Biomaterials. 2005 Jan;26(2):205-10
pubmed: 15207467
Drug Deliv. 2016 Jun;23(5):1608-22
pubmed: 26758033
J Am Acad Dermatol. 1993 Nov;29(5 Pt 1):736-40
pubmed: 8227546
J Invest Dermatol. 1994 Jul;103(1):97-103
pubmed: 8027588
J Liposome Res. 2012 Dec;22(4):336-45
pubmed: 22881283
Int J Pharm. 2011 Jul 15;413(1-2):202-10
pubmed: 21540093
Pediatr Dermatol. 2017 Jan;34(1):13-24
pubmed: 27878842
J Pharm Sci. 2010 Apr;99(4):2049-60
pubmed: 19780133
Dermatol Ther. 2010 Jul-Aug;23(4):428-34
pubmed: 20666832
AAPS PharmSciTech. 2012 Sep;13(3):826-35
pubmed: 22644706
Drug Dev Ind Pharm. 2018 Nov;44(11):1809-1816
pubmed: 29969300
Drug Deliv. 2016 Oct;23(8):2813-2819
pubmed: 26447337
Pharm Dev Technol. 2017 Jun;22(4):545-550
pubmed: 26895257
Sci Rep. 2017 Aug 30;7(1):9910
pubmed: 28855590
Int J Biol Macromol. 2016 Dec;93(Pt A):591-599
pubmed: 27620464
J Eur Acad Dermatol Venereol. 2007 May;21(5):638-42
pubmed: 17447977
Pharm Dev Technol. 2013 May-Jun;18(3):673-85
pubmed: 22612232
Curr Drug Deliv. 2018;15(6):907-916
pubmed: 29359666
Int J Pharm. 2018 Mar 25;539(1-2):83-94
pubmed: 29374518
J Microencapsul. 2008 Oct;25(7):499-512
pubmed: 18608811
Int J Pharm. 2009 Jul 30;377(1-2):1-8
pubmed: 19394413
J Photochem Photobiol B. 2013 Aug 5;125:146-54
pubmed: 23816959
J Am Acad Dermatol. 1997 Apr;36(4):577-81
pubmed: 9092744
Photodermatol Photoimmunol Photomed. 2011 Oct;27(5):261-77
pubmed: 21950634
J Microencapsul. 2009 Dec;26(8):684-91
pubmed: 19888877
Int J Dermatol. 2012 Sep;51(9):1107-15
pubmed: 22909369
Int J Dermatol. 2005 Jan;44(1):57-60
pubmed: 15663664
Photodermatol Photoimmunol Photomed. 2003 Feb;19(1):1-4
pubmed: 12713546
J Phys Chem B. 2008 Nov 6;112(44):14002-10
pubmed: 18855465
Photodermatol Photoimmunol Photomed. 2013 Dec;29(6):311-7
pubmed: 24118425
Eur J Pharm Sci. 2017 Apr 1;101:258-268
pubmed: 28232140
Curr Drug Deliv. 2018;15(7):953-964
pubmed: 29446743
Int J Dermatol. 2000 Nov;39(11):865-7
pubmed: 11123453

Auteurs

Mai Shaaban (M)

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

Maha Nasr (M)

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. drmahanasr@pharma.asu.edu.eg.

Abeer Attia Tawfik (AA)

Dermatology and Laser Dermatology Unit, Department of Medical Applications of Laser, National Institute of Laser Enhanced Sciences, Cairo University, Cairo, Egypt.

Maha Fadel (M)

Pharmaceutical Technology Unit, Department of Medical Applications of Laser, National Institute of Laser Enhanced Sciences, Cairo University, Cairo, Egypt.

Omaima Sammour (O)

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH